AMR Research Programme, the AMR Benchmark Report
The 2021 Antimicrobial Resistance Benchmark assesses and compares how pharmaceutical companies are tackling AMR. This independent report covers R&D, responsible manufacturing, access and stewardship.
Track the progress and gaps in their efforts of companies to keep medicines and vaccines available, despite the rise of drug resistance.
- Antimicrobial stewardship
- Antimicrobial compound/strategy
- Removal antibiotics/bacteria
- Infection prevention
- Microbial diagnostics
- Market entry
- Marketed product
- Joint Venture
- OTHER / NA
Infectious disease area:
- North America
- South America
The Foundation works with pharmaceutical companies to gather data to report on activities, initiatives and progress as relevant.
We stimulate and guide pharmaceutical companies to do more for vulnerable populations without access to medicine.
Short thematic reports to provide an assessment of the current state and recommendations to key stakeholders on next steps to curbing AMR.